Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAbivax Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.85 | -$0.82 | -$0.84 |
| Q2 2026 | 3 | -$1.10 | -$0.60 | -$0.84 |
| Q1 2027 | 1 | -$0.92 | -$0.92 | -$0.92 |
| Q2 2027 | 1 | -$1.23 | -$1.23 | -$1.23 |
| Q1 2028 | 2 | -$1.52 | -$1.52 | -$1.52 |
| Q2 2028 | 1 | -$1.51 | -$1.51 | -$1.51 |
| Q1 2029 | 1 | -$1.47 | -$1.47 | -$1.47 |
| Q2 2029 | 1 | -$1.41 | -$1.41 | -$1.41 |
Abivax Earnings Date And Information
Abivax last posted its earnings results on Friday, May 22nd, 2026. The company reported $-0.71 earnings per share for the quarter, topping analysts' consensus estimates of $-1.07 by $0.36. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Abivax has generated $-5 earnings per share over the last year ($-4.65 diluted earnings per share) and currently has a price-to-earnings ratio of -20.49. Abivax has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Abivax Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/23/2026 | Q4 2025 | -$1.70 | -$2.10 | -0.4 | $348.50 K | $0 |
| 09/08/2025 | Q2 2025 | -$0.90 | -$1.59 | -0.69 | $1.18 M | $0 |
| 03/24/2025 | Q4 2024 | -$0.76 | -$1.50 | -0.74 | $3.09 M | $0 |
| 06/30/2024 | Q2 2024 | N/A | -$0.65 | N/A | $3.41 M | $0 |
| 12/29/2023 | Q4 2023 | N/A | -$1.98 | N/A | $1.11 M | $2.33 M |
| 06/29/2023 | Q2 2023 | N/A | -$1.45 | N/A | $1.15 M | $2.25 M |
| 12/30/2022 | Q4 2022 | N/A | -$1.81 | N/A | N/A | $2.25 M |
| 06/29/2022 | Q2 2022 | N/A | -$1.76 | N/A | N/A | $2.23 M |
| 12/30/2021 | Q4 2021 | N/A | -$1.48 | N/A | N/A | $0 |
| 06/29/2021 | Q2 2021 | N/A | -$1.13 | N/A | N/A | $0 |
| 12/30/2020 | Q4 2020 | N/A | -$1.55 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$1.26 | N/A | N/A | $0 |
| 12/30/2019 | Q4 2019 | N/A | -$1.35 | N/A | N/A | $0 |
| 06/29/2019 | Q2 2019 | N/A | -$1.38 | N/A | N/A | $0 |
| 12/31/2018 | Q4 2018 | N/A | -$0.82 | N/A | N/A | $323.00 K |
| 06/30/2018 | Q2 2018 | N/A | -$0.73 | N/A | N/A | $492.00 K |
| 12/31/2017 | Q4 2017 | N/A | -$0.56 | N/A | N/A | $352.00 K |
| 06/30/2017 | Q2 2017 | N/A | -$0.57 | N/A | N/A | $4.00 K |
| 12/31/2016 | Q4 2016 | N/A | -$0.61 | N/A | N/A | $14.00 K |
| 06/30/2016 | Q2 2016 | N/A | -$0.86 | N/A | N/A | $137.00 K |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Abivax Earnings: FAQ's
In the previous quarter, Abivax (:ABVX) reported $-0.71 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.07 by $0.36.
The conference call for Abivax's latest earnings report can be listened to online.
The conference call transcript for Abivax's latest earnings report can be read online.
Abivax (:ABVX) has a recorded net income of $-336,102,000.Abivax has generated $-4.65 earnings per share over the last four quarters.
Abivax (:ABVX) has a price-to-earnings ratio of -20.49 and price/earnings-to-growth ratio is 0.34.